Review ArticleSystematic Review
Open Access

High serum uric acid levels may increase mortality and major adverse cardiovascular events in patients with acute myocardial infarction

Qiyao Xu, Mei Zhang, Iruni R. Abeysekera and Xiaolong Wang
Saudi Medical Journal June 2017, 38 (6) 577-585; DOI: https://doi.org/10.15537/smj.2017.6.17190

References

  1. ↵
    1. Jernberg T,
    2. Johanson P,
    3. Held C,
    4. Svennblad B,
    5. Lindbäck J,
    6. Wallentin L
    (2011) Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction. JAMA 305:1677–1684.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Becker BF
    (1993) Towards the physiological function of uric acid. Free Radic Biol Med 14:615–631.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Gavin AR,
    2. Struthers AD
    (2003) Hyperuricemia and adverse outcomes in cardiovascular disease: potential for therapeutic intervention. Am J Cardiovasc Drugs 3:309–314.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Karalius VP,
    2. Shoham DA
    (2013) Dietary sugar and artificial sweetener intake and chronic kidney disease: a review. Adv Chronic Kidney Dis 20:157–164.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Kuwabara M
    (2016) Hyperuricemia, Cardiovascular Disease, and Hypertension. Pulse (Basel) 3:242–252.
    OpenUrl
  6. ↵
    1. Braga F,
    2. Pasqualetti S,
    3. Ferraro S,
    4. Panteghini M
    (2016) Hyperuricemia as risk factor for coronary heart disease incidence and mortality in the general population: a systematic review and meta-analysis. Clin Chem Lab Med 54:7–15.
    OpenUrl
  7. ↵
    1. Kim SY,
    2. Guevara JP,
    3. Kim KM,
    4. Choi HK,
    5. Heitjan DF,
    6. Albert DA
    (2010) Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 62:170–180.
    OpenUrl
  8. ↵
    1. Feig DI,
    2. Kang DH,
    3. Johnson RJ
    (2008) Uric acid and cardiovascular risk. N Engl J Med 359:1811–1821.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Yan L,
    2. Liu Z,
    3. Zhang C
    (2014) Uric acid as a predictor of in-hospital mortality in acute myocardial infarction: a meta-analysis. Cell Biochem Biophys 70:1597–1601.
    OpenUrl
  10. ↵
    1. Trkulja V,
    2. Car S
    (2012) On-admission serum uric acid predicts outcomes after acute myocardial infarction: systematic review and meta-analysis of prognostic studies. Croat Med J 53:162–172.
    OpenUrlPubMed
  11. ↵
    1. Stroup DF,
    2. Berlin JA,
    3. Morton SC,
    4. Olkin I,
    5. Williamson GD,
    6. Rennie D,
    7. et al.
    (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008–2012.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Stang A
    (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysis. Eur J Epidemiol 25:603–605.
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    1. DerSimonian R,
    2. Laird N
    (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188.
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Higgins JP
    (2008) Commentary: Heterogeneity in meta-analysis should be expected and appropriately quantified. Int J Epidemiol 37:1158–1160.
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Higgins JP,
    2. Thompson SG,
    3. Deeks JJ,
    4. Altman DG
    (2003) Measuring inconsistency in meta-analysis. BMJ 327:557–560.
    OpenUrlFREE Full Text
  16. ↵
    1. Sterne JA,
    2. Egger M,
    3. Smith GD
    (2001) Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. BMJ 323:101–105.
    OpenUrlFREE Full Text
  17. ↵
    1. Sterne JA,
    2. Egger M
    (2001) Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 54:1046–1055.
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    1. Gazi E,
    2. Temiz A,
    3. Altun B,
    4. Barutçu A,
    5. Bekler A,
    6. Güngör O,
    7. et al.
    (2014) The association between serum uric acid level and heart failure and mortality in the early period of ST-elevation acute myocardial infarction. Turk Kardiyol Dern Ars 42:501–508.
    OpenUrl
  19. ↵
    1. Akgul O,
    2. Uyarel H,
    3. Pusuroglu H,
    4. Gul M,
    5. Isiksacan N,
    6. Turen S,
    7. et al.
    (2014) Predictive Value of Elevated Uric Acid in Turkish Patients Undergoing Primary Angioplasty for ST Elevation Myocardial Infarction. Acta Cardiol Sin 30:119–127.
    OpenUrl
  20. ↵
    1. Lazzeri C,
    2. Valente S,
    3. Chiostri M,
    4. Picariello C,
    5. Gensini GF
    (2012) Uric acid in the early risk stratification of ST-elevation myocardial infarction. Intern Emerg Med 7:33–39.
    OpenUrlPubMed
  21. ↵
    1. Omidvar B,
    2. Ayatollahi F,
    3. Alasti M
    (2012) The prognostic role of serum uric acid level in patients with acute ST elevation myocardial infarction. J Saudi Heart Assoc 24:73–78.
    OpenUrl
  22. ↵
    1. Chen L,
    2. Li XL,
    3. Qiao W,
    4. Ying Z,
    5. Qin YL,
    6. Wang Y,
    7. et al.
    (2012) Serum uric acid in patients with acute ST-elevation myocardial infarction. World J Emerg Med 3:35–39.
    OpenUrl
  23. ↵
    1. Kaya MG,
    2. Uyarel H,
    3. Akpek M,
    4. Kalay N,
    5. Ergelen M,
    6. Ayhan E,
    7. et al.
    (2012) Prognostic value of uric acid in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Am J Cardiol 109:486–491.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Akpek M,
    2. Kaya MG,
    3. Uyarel H,
    4. Yarlioglues M,
    5. Kalay N,
    6. Gunebakmaz O,
    7. et al.
    (2011) The association of serum uric acid levels on coronary flow in patients with STEMI undergoing primary PCI. Atherosclerosis 219:334–341.
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    1. Bae MH,
    2. Lee JH,
    3. Lee SH,
    4. Park SH,
    5. Yang DH,
    6. Park HS,
    7. et al.
    (2011) Serum uric acid as an independent and incremental prognostic marker in addition to N-terminal pro-B-type natriuretic peptide in patients with acute myocardial infarction. Circ J 75:1440–1447.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Basar N,
    2. Sen N,
    3. Ozcan F,
    4. Erden G,
    5. Kanat S,
    6. Sokmen E,
    7. et al.
    (2011) Elevated serum uric acid predicts angiographic impaired reperfusion and 1-year mortality in ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention. J Investig Med 59:931–937.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Lazzeri C,
    2. Valente S,
    3. Chiostri M,
    4. Sori A,
    5. Bernardo P,
    6. Gensini GF
    (2010) Uric acid in the acute phase of ST elevation myocardial infarction submitted to primary PCI: its prognostic role and relation with inflammatory markers: a single center experience. Int J Cardiol 138:206–209.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Kowalczyk J,
    2. Francuz P,
    3. Swoboda R,
    4. Lenarczyk R,
    5. Sredniawa B,
    6. Golda A,
    7. et al.
    (2010) Prognostic significance of hyperuricemia in patients with different types of renal dysfunction and acute myocardial infarction treated with percutaneous coronary intervention. Nephron Clin Pract 116:c114–c122.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Car S,
    2. Trkulja V
    (2009) Higher serum uric acid on admission is associated with higher short-term mortality and poorer long-term survival after myocardial infarction: retrospective prognostic study. Croat Med J 50:559–566.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Kojima S,
    2. Sakamoto T,
    3. Ishihara M,
    4. Kimura K,
    5. Miyazaki S,
    6. Yamagishi M,
    7. et al.
    (2005) Prognostic usefulness of serum uric acid after acute myocardial infarction (the Japanese Acute Coronary Syndrome Study). Am J Cardiol 96:489–495.
    OpenUrlCrossRefPubMedWeb of Science
  31. ↵
    1. Oh J,
    2. Won HY,
    3. Kang SM
    (2009) Uric acid and cardiovascular risk. N Engl J Med 360:539–540, author reply 540-541.
    OpenUrlPubMedWeb of Science
    1. Johnson RJ,
    2. Kang DH,
    3. Feig D,
    4. Kivlighn S,
    5. Kanellis J,
    6. Watanabe S,
    7. et al.
    (2003) Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 41:1183–1190.
    OpenUrlCrossRefPubMed
    1. George J,
    2. Carr E,
    3. Davies J,
    4. Belch JJ,
    5. Struthers A
    (2006) High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 114:2508–2516.
    OpenUrlAbstract/FREE Full Text
    1. Doehner W,
    2. Anker SD
    (2005) Xanthine oxidase inhibition for chronic heart failure: is allopurinol the next therapeutic advance in heart failure. Heart 91:707–709.
    OpenUrlAbstract/FREE Full Text
    1. Souza-Junior T,
    2. Lorenço-Lima L,
    3. Ganini D,
    4. Vardaris C,
    5. Polotow T,
    6. Barros M
    (2014) Delayed uric Acid accumulation in plasma provides additional anti-oxidant protection against iron-triggered oxidative stress after a wingate test. Biol Sport 31:271–276.
    OpenUrl
  36. ↵
    1. Nihei H,
    2. Kanemitsu H,
    3. Tamura A,
    4. Oka H,
    5. Sano K
    (1989) Cerebral uric acid, xanthine, and hypoxanthine after ischemia: the effect of allopurinol. Neurosurgery 25:613–617.
    OpenUrlCrossRefPubMed
  37. ↵
    1. von LTG,
    2. Girerd N,
    3. Atar D,
    4. Agewall S,
    5. Lamiral Z,
    6. Kanbay M,
    7. et al.
    (2015) Serum uric acid is associated with mortality and heart failure hospitalizations in patients with complicated myocardial infarction: findings from the High-Risk Myocardial Infarction Database Initiative. Eur J Heart Fail 17:1144–1151.
    OpenUrl
  38. ↵
    1. Levantesi G,
    2. Marfisi RM,
    3. Franzosi MG,
    4. Maggioni AP,
    5. Nicolosi GL,
    6. Schweiger C,
    7. et al.
    (2013) Uric acid: a cardiovascular risk factor in patients with recent myocardial infarction. Int J Cardiol 167:262–269.
    OpenUrl
  39. ↵
    1. Baumann S,
    2. Huseynov A,
    3. Koepp J,
    4. Jabbour C,
    5. Behnes M,
    6. Becher T,
    7. et al.
    (2016) Comparison of Serum Uric Acid, Bilirubin, and C-Reactive Protein as Prognostic Biomarkers of In-Hospital MACE Between Women and Men With ST-Segment Elevation Myocardial Infarction. Angiology 67:272–280.
    OpenUrlCrossRefPubMed
    1. Holme I,
    2. Aastveit AH,
    3. Hammar N,
    4. Jungner I,
    5. Walldius G
    (2009) Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417,734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med 266:558–570.
    OpenUrlCrossRefPubMedWeb of Science
  41. ↵
    1. Tatli E,
    2. Aktoz M,
    3. Buyuklu M,
    4. Altun A
    (2008) The relationship between coronary artery disease and uric acid levels in young patients with acute myocardial infarction. Cardiol J 15:21–25.
    OpenUrlPubMed
  42. ↵
    1. Elisaf M,
    2. Tsimichodimos V,
    3. Bairaktari E,
    4. Siamopoulos KC
    (1999) Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia. J Cardiovasc Pharmacol 34:60–63.
    OpenUrlCrossRefPubMedWeb of Science
    1. Desager JP,
    2. Hulhoven R,
    3. Harvengt C
    (1980) Uricosuric effect of fenofibrate in healthy volunteers. J Clin Pharmacol 20:560–564.
    OpenUrlPubMedWeb of Science
  44. ↵
    1. Grassi D,
    2. Ferri L,
    3. Desideri G,
    4. Di Giosia P,
    5. Cheli P,
    6. Del Pinto R,
    7. et al.
    (2013) Chronic hyperuricemia, uric acid deposit and cardiovascular risk. Curr Pharm Des 19:2432–2438.
    OpenUrlPubMed
  45. ↵
    1. Onat A,
    2. Uyarel H,
    3. Hergenç G,
    4. Karabulut A,
    5. Albayrak S,
    6. Sari I,
    7. et al.
    (2006) Serum uric acid is a determinant of metabolic syndrome in a population-based study. Am J Hypertens 19:1055–1062.
    OpenUrlCrossRefPubMed
  46. ↵
    1. Høieggen A,
    2. Alderman MH,
    3. Kjeldsen SE,
    4. Julius S,
    5. Devereux RB,
    6. De Faire U,
    7. et al.
    (2004) The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 65:1041–1049.
    OpenUrlCrossRefPubMedWeb of Science
    1. Escobar C,
    2. Barrios V,
    3. Calderón A,
    4. Barrios S,
    5. Echarri R,
    6. Navarro-Cid J,
    7. et al.
    (2008) Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with the metabolic syndrome: data from the SARA Study. J Clin Hypertens (Greenwich) 10:208–214.
    OpenUrlPubMed
  48. ↵
    1. Athyros VG,
    2. Mikhailidis DP,
    3. Liberopoulos EN,
    4. Kakafika AI,
    5. Karagiannis A,
    6. Papageorgiou AA,
    7. et al.
    (2007) Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 22:118–127.
    OpenUrlCrossRefPubMedWeb of Science
  49. ↵
    1. Feig DI,
    2. Soletsky B,
    3. Johnson RJ
    (2008) Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 300:924–932.
    OpenUrlCrossRefPubMedWeb of Science
  50. ↵
    1. Grundy SM,
    2. Hansen B,
    3. Smith SC,
    4. Cleeman JI,
    5. Kahn RA
    (2004) Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 109:551–556.
    OpenUrlFREE Full Text
  51. ↵
    1. Yildiz BS,
    2. Ozkan E,
    3. Esin F,
    4. Alihanoglu YI,
    5. Ozkan H,
    6. Bilgin M,
    7. et al.
    (2016) Does high serum uric acid level cause aspirin resistance? Blood Coagul Fibrinolysis 27:412–418.
    OpenUrl
  52. ↵
    1. Barbieri L,
    2. Verdoia M,
    3. Pergolini P,
    4. Nardin M,
    5. Rolla R,
    6. Marino P,
    7. et al.
    (2016) Uric acid and high-residual platelet reactivity in patients treated with clopidogrel or ticagrelor. Nutr Metab Cardiovasc Dis 26:352–358.
    OpenUrl
  53. ↵
    1. Nardin M,
    2. Verdoia M,
    3. Pergolini P,
    4. Rolla R,
    5. Barbieri L,
    6. Schaffer A,
    7. et al.
    (2016) Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study. Nutr Metab Cardiovasc Dis 26:567–574.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section